Skip to Main Content

Paper Details

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Breast Cancer Res Treat
3
2019
Exemestane, HR, HR+, Letrozole, UGT2B17, UGT2B17 gene, UGT2B17 gene deletion, UGT2B17 genotype, UGT2B17*, UGT2B17*2, UGT2B17*2 gene deletion, aromatase, breast cancer, exemestane, letrozole, patients, women
Author NameAffiliation
Kelley M KidwellUniversity of Michigan School of Public Health ann arbor
Anna Maria StornioloMelvin and Bren Simon Cancer Center, Indiana University School of Medicine
Vered StearnsThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • 1 - 3

Datasets

Release 1.2